Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.2795
+0.00461.67%
Volume:26.69M
Turnover:7.52M
Market Cap:7.80M
PE:-0.07
High:0.2951
Open:0.2900
Low:0.2729
Close:0.2749
52wk High:14.80
52wk Low:0.2729
Shares:27.90M
Float Shares:26.23M
Volume Ratio:19.65
T/O Rate:101.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.24
PE(LYR):-0.06

Loading ...

VolitionRX Announces Acceptance of Compliance Plan by Nyse American

THOMSON REUTERS
·
Apr 23

VolitionRX Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
Apr 20

VolitionRx downgraded to Hold from Buy at D. Boral Capital

TIPRANKS
·
Apr 20

VolitionRx effects 1-for-20 reverse stock split April 28

Reuters
·
Apr 18

VolitionRX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 03

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

TIPRANKS
·
Apr 03

VolitionRx shareholders approved reverse stock split authorization at special meeting

Reuters
·
Apr 02

VolitionRx publishes corporate presentation outlining Nu.Q licensing-led cancer and sepsis diagnostics strategy

Reuters
·
Apr 01

VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

Benzinga Earnings
·
Apr 01

VolitionRx FY25 net loss narrows 14%; revenue rises 40% to $1.7 million

Reuters
·
Apr 01

Press Release: VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Dow Jones
·
Apr 01

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

VolitionRX Ltd - Secures €2.0 Mln Non-Dilutive Funding From Belgian Regional Agencies

THOMSON REUTERS
·
Mar 31

Press Release: VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Dow Jones
·
Mar 31

VolitionRx study shows Nu.Q nucleosome biomarkers elevated in trauma patients, linked to VTE

Reuters
·
Mar 30

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification

Reuters
·
Mar 26

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

THOMSON REUTERS
·
Mar 26

VolitionRx schedules FY2025 earnings conference call; business update webcast opens to investors

Reuters
·
Mar 26

VolitionRx reports Capture-Seq blinded validation sensitivity rises to 93%; specificity climbs to 95%

Reuters
·
Mar 25